BioCryst Launches Orladeyo (berotralstat) in Spain Biocryst Pharmaceuticals Inc today announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted marketing authorization for oral, once-daily Orladeyo (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “We have an experienced and motivated team in [...]
European Commission approves label update for lanadelumab, for a broader group of pediatric patients with recurrent attacks of hereditary angioedema (HAE) Takeda today announced the European Commission has approved Takhzyro (lanadelumab) for the routine prevention of recurrent attacks of Hereditary Angioedema (HAE) in patients aged 2 years and older, expanding its initial approved use [...]
Intellia Therapeutics receives European Union orphan drug designation for NTLA-2002, an investigational in-vivo CRISPR genome editing treatment for Hereditary Angioedema Intellia Therapeutics today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent [...]
KalVista Pharmaceuticals presents real-world data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology KalVista Pharmaceuticals presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema (HAE) attacks and patient perspectives on why people living with HAE don’t often carry their on-demand [...]
Orchard Therapeutics reports third quarter 2023 financial results and highlights recent business accomplishments Orchard Therapeutics announced several business accomplishments along with its financial results for the quarter ended 30 September 2023. Bobby Gaspar MD PhD, Chief Executive Officer of Orchard Therapeutics, said: “With strong execution across our key commercial, regulatory and clinical priorities, 2023 [...]
Astria Therapeutics reports third quarter financial results and provides a corporate update Astra Therapeutics reported financial results for the third quarter ended 30 September 2023 and provided a corporate update. Jill C. Milne, PhD, Chief Executive Officer at Astria Therapeutics, said: “We are realizing our vision of growing an allergy and immunology company with [...]
Kalvista Pharmaceuticals announces Phase-3 KONFIDENT trial milestone achieved KalVista Pharmaceuticals provided clinical trial and regulatory updates for its lead program sebetralstat, in development as a potential oral on-demand therapy for hereditary angioedema (HAE). Clinical Trial and Regulatory Updates: KalVista has achieved the targeted number of on-treatment attacks required to complete the phase 3 KONFIDENT [...]
Please join us in welcoming yet another member country to the global HAE family: HAE Mozambique as member country no. 98. The national contact is Daniella Nhaguilunguana. >> Read more about HAE Mozambique on the country page Daniella shared her story as part of the Patient Voices session at the 2023 HAEi Regional Conference EMEA.
From Director Fiona Wardman, HAE Australasia HAE Australasia has a new CEO! Lisa Foster is an inclusive and authentic leader with extensive experience across Health, Disability, Mental Health, and Community Support Sectors. Lisa was the Chief Executive for Rare Disorders New Zealand and has a background in biomedical science. As a veteran of advocating [...]
HAEi is delighted to have welcomed HAE Kosovo as country no. 97 to join the global HAE family. The national contact is Edison Sylejmani. >> You can read more about HAE Kosovo on the country page In our 2023 HAEi Regional Conference EMEA Scientific Track, Dr. Rushit Ismajli presented a poster describing the first identified [...]
HAE International is a global non-profit network of member organizations dedicated to raising awareness of hereditary angioedema and improving the lives of people with HAE.
HAE International (HAEi)
10560 Main Street, Ste PS40
Fairfax City, VA 22030
United States of America
gro.ieah@ofni
HAE International (HAEi)
Vejlevej 16, 1.
8700 Horsens
Denmark
gro.ieah@ofni
